Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Revolution Medicines (RVMD) EBT (2019 - 2025)

Revolution Medicines has reported EBT over the past 7 years, most recently at -$364.9 million for Q4 2025.

  • Quarterly results put EBT at -$364.9 million for Q4 2025, down 189.99% from a year ago — trailing twelve months through Dec 2025 was -$1.1 billion (down 2262502.0% YoY), and the annual figure for FY2025 was -$1.1 billion, down 2262502.0%.
  • EBT for Q4 2025 was -$364.9 million at Revolution Medicines, down from -$305.2 million in the prior quarter.
  • Over the last five years, EBT for RVMD hit a ceiling of $405.5 million in Q4 2024 and a floor of -$364.9 million in Q4 2025.
  • Median EBT over the past 5 years was -$86.0 million (2022), compared with a mean of -$100.4 million.
  • Biggest five-year swings in EBT: skyrocketed 351.54% in 2024 and later plummeted 189.99% in 2025.
  • Revolution Medicines' EBT stood at -$52.7 million in 2021, then fell by 7.51% to -$56.6 million in 2022, then crashed by 184.64% to -$161.2 million in 2023, then skyrocketed by 351.54% to $405.5 million in 2024, then plummeted by 189.99% to -$364.9 million in 2025.
  • The last three reported values for EBT were -$364.9 million (Q4 2025), -$305.2 million (Q3 2025), and -$247.8 million (Q2 2025) per Business Quant data.